Top Markets
Coin of the day
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc.

NGM
Rang in Aktien #20909
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering... NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.
Aktienkurs
$1.54
Zuletzt synchronisiert: 2024-04-08
Marktkapitalisierung
$119.21M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel NGM Biopharmaceuticals, Inc. (NGM)

Kategorie

Preis NGM mit Marktkapitalisierung von B
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
NGM
$1.54
Marktkapitalisierung von NGM Biopharmaceuticals, Inc.(NGM)
Marktkapitalisierung: $119.21M
Mit Stand August 2026 hat NGM Biopharmaceuticals, Inc. eine Marktkapitalisierung von $119.21M. Das macht NGM Biopharmaceuticals, Inc. laut unseren Daten zum 20909th wertvollsten Unternehmen der Welt nach Marktkapitalisierung. Die Marktkapitalisierung ist der Gesamtmarktwert aller ausstehenden Aktien eines börsennotierten Unternehmens und wird häufig verwendet, um den Unternehmenswert zu bestimmen.
Marktkapitalisierung von NGM Biopharmaceuticals, Inc. von 2019 bis 2026
NGM im Vergleich zu den Top 5 der beliebtesten stocks
Preis für NGM Vermögenswert B Marktkapitalisierung von B Ergebnisse
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
$67,322.89 $119.21M
$5.211T +4,371,516.28%
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
$58,736.98 $119.21M
$4.547T +3,813,989.78%
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
$53,772.80 $119.21M
$4.162T +3,491,640.48%
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
$46,413.34 $119.21M
$3.593T +3,013,753.51%
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.
$36,079.39 $119.21M
$2.793T +2,342,717.73%